Wellgistics 2025 Q3 Earnings Deepening Losses as Net Income Plummets 1738%

Wellgistics (WGRX) reported fiscal 2025 Q3 results on Nov 19, 2025, with a 46.9% revenue decline to $3.01 million and a net loss of $34.32 million, representing a 1738% year-over-year increase in losses. The CEO acknowledged operational challenges and emphasized long-term strategic investments, while the stock saw a 34.78% month-to-date rally.

Revenue

Wellgistics’ total revenue fell sharply to $3.01 million in Q3 2025, a 46.9% drop from $5.67 million in the prior-year period. Distribution services remained the core driver, contributing $2.64 million, while pharmacy retail sales and third-party logistics services added $172,100 and $203,014, respectively. The decline was attributed to reduced sales volume and macroeconomic headwinds.

Earnings/Net Income

The company’s losses widened dramatically, with a net loss of $34.32 million in Q3 2025—1738.1% higher than $1.87 million in 2024 Q3. Earnings per share (EPS) turned to a $0.46 loss, up from $0.04, reflecting a 1050% deterioration. Despite the record net loss, the CEO noted a focus on long-term innovation in chronic disease management.

Price Action

WGRX’s stock closed 1.30% lower on the latest trading day but gained 1.44% over the preceding week and surged 34.78% month-to-date.

Post-Earnings Price Action Review

The strategy of buying WGRX shares on revenue announcements and holding for 30 days showed mixed performance over three years. While the first year delivered a 10.2% gain, subsequent years posted 2.5% and 1.8% losses. Quarterly volatility highlighted short-term potential and risks, though the absence of market benchmark comparisons limited the strategy’s evaluative clarity.

CEO Commentary

The CEO emphasized challenges in scaling revenue amid macroeconomic pressures, noting a $34.3 million net loss and $3.01 million in revenue. Strategic investments in digital health infrastructure and partnerships were cited as key to long-term value creation, alongside cautious optimism about telehealth adoption.

Guidance

Management anticipates sequential revenue growth in Q4 2025 through expanded service offerings and client retention initiatives but did not provide quantitative targets. Focus remains on fiscal discipline and R&D in AI-driven patient analytics to enhance competitive differentiation.

Additional News

Wellgistics Health, Inc. filed its 2025 Q3 10-Q report, disclosing a $34.32 million net loss and $3.01 million in revenues—a 46.9% decline from 2024. The report flagged significant financial challenges, including a $31.55 million operational loss and concerns about the company’s ability to continue as a going concern. All revenues were generated domestically, with distribution services ($2.64 million) outpacing pharmacy retail sales ($172,100) and third-party logistics ($203,014).